BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17172419)

  • 1. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
    Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
    Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATM-dependent CHK2 activation induced by anticancer agent, irofulven.
    Wang J; Wiltshire T; Wang Y; Mikell C; Burks J; Cunningham C; Van Laar ES; Waters SJ; Reed E; Wang W
    J Biol Chem; 2004 Sep; 279(38):39584-92. PubMed ID: 15269203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
    Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
    Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Jacquemont C; Taniguchi T
    Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irofulven induces replication-dependent CHK2 activation related to p53 status.
    Wang Y; Wiltshire T; Senft J; Reed E; Wang W
    Biochem Pharmacol; 2007 Feb; 73(4):469-80. PubMed ID: 17118344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance.
    Ho GP; Margossian S; Taniguchi T; D'Andrea AD
    Mol Cell Biol; 2006 Sep; 26(18):7005-15. PubMed ID: 16943440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATR couples FANCD2 monoubiquitination to the DNA-damage response.
    Andreassen PR; D'Andrea AD; Taniguchi T
    Genes Dev; 2004 Aug; 18(16):1958-63. PubMed ID: 15314022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FANCD2 Binds Human Papillomavirus Genomes and Associates with a Distinct Set of DNA Repair Proteins to Regulate Viral Replication.
    Spriggs CC; Laimins LA
    mBio; 2017 Feb; 8(1):. PubMed ID: 28196964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinated action of the Fanconi anemia and ataxia telangiectasia pathways in response to oxidative damage.
    Castillo P; Bogliolo M; Surralles J
    DNA Repair (Amst); 2011 May; 10(5):518-25. PubMed ID: 21466974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.
    Landais I; Hiddingh S; McCarroll M; Yang C; Sun A; Turker MS; Snyder JP; Hoatlin ME
    Mol Cancer; 2009 Dec; 8():133. PubMed ID: 20043851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.
    Shen C; Oswald D; Phelps D; Cam H; Pelloski CE; Pang Q; Houghton PJ
    Cancer Res; 2013 Jun; 73(11):3393-401. PubMed ID: 23633493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Fanconi anemia ID2 complex: dueling saxes at the crossroads.
    Boisvert RA; Howlett NG
    Cell Cycle; 2014; 13(19):2999-3015. PubMed ID: 25486561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR/ATM pathways.
    Sobeck A; Stone S; Landais I; de Graaf B; Hoatlin ME
    J Biol Chem; 2009 Sep; 284(38):25560-8. PubMed ID: 19633289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway.
    Ishiai M; Kitao H; Smogorzewska A; Tomida J; Kinomura A; Uchida E; Saberi A; Kinoshita E; Kinoshita-Kikuta E; Koike T; Tashiro S; Elledge SJ; Takata M
    Nat Struct Mol Biol; 2008 Nov; 15(11):1138-46. PubMed ID: 18931676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential roles for Chk1 and FANCD2 in ATR-mediated signalling for psoralen photoactivation-induced senescence.
    Hovest MG; Krieg T; Herrmann G
    Exp Dermatol; 2011 Nov; 20(11):883-9. PubMed ID: 21995812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia.
    Guervilly JH; Macé-Aimé G; Rosselli F
    Hum Mol Genet; 2008 Mar; 17(5):679-89. PubMed ID: 18029388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways.
    Taniguchi T; Garcia-Higuera I; Xu B; Andreassen PR; Gregory RC; Kim ST; Lane WS; Kastan MB; D'Andrea AD
    Cell; 2002 May; 109(4):459-72. PubMed ID: 12086603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ATR- and BRCA1-mediated Fanconi anemia pathway is required for activating the G2/M checkpoint and DNA damage repair upon rereplication.
    Zhu W; Dutta A
    Mol Cell Biol; 2006 Jun; 26(12):4601-11. PubMed ID: 16738325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo.
    Wang HC; Lee AY; Chou WC; Wu CC; Tseng CN; Liu KY; Lin WL; Chang FR; Chuang DW; Hunyadi A; Wu YC
    Mol Cancer Ther; 2012 Jul; 11(7):1443-53. PubMed ID: 22532598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk human papillomavirus oncogenes disrupt the Fanconi anemia DNA repair pathway by impairing localization and de-ubiquitination of FancD2.
    Khanal S; Galloway DA
    PLoS Pathog; 2019 Feb; 15(2):e1007442. PubMed ID: 30818369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.